https://scholars.lib.ntu.edu.tw/handle/123456789/558306
標題: | Chronic Metformin Therapy is Associated with a Lower Risk of Hemorrhoid in Patients with Type 2 Diabetes Mellitus | 作者: | CHIN-HSIAO TSENG | 關鍵字: | diabetes mellitus; hemorrhoid; metformin; National Health Insurance; pharmacoepidemiology; Taiwan | 公開日期: | 2021 | 出版社: | Frontiers Media S.A. | 卷: | 11 | 起(迄)頁: | 578831 | 來源出版物: | Frontiers in Pharmacology | 摘要: | Background: Metformin has anti-inflammatory property and reduces the risk of varicose vein in our previous study. Aim: To investigate the risk of hemorrhoid, another common disease involving the hemorrhoidal venous plexus, in ever vs. never users of metformin in patients with type 2 diabetes mellitus. Methods: This is a population-based retrospective cohort study. Patients with new-onset type 2 diabetes mellitus during 1999–2005 were enrolled from Taiwan’s National Health Insurance. All patients who were alive on January 1, 2006 were followed up until December 31, 2011. Analyses were conducted in both an unmatched cohort of 152,347 ever users and 19,523 never users and in 19,498 propensity score (PS)-matched pairs of ever and never users. Traditional Cox regression and Cox regression incorporated with the inverse probability of treatment weighting (IPTW) using the PS were used to estimate hazard ratios. Results: New-onset hemorrhoid was diagnosed in 8,211 ever users and 2025 never users in the unmatched cohort and in 1,089 ever users and 2022 never users in the matched cohort. The hazard ratio for ever vs. never users derived from the traditional Cox regression was 0.464 (95% confidence interval: 0.440–0.488) in the unmatched cohort; and was 0.488 (0.453–0.525) in the matched cohort. In the IPTW models, the hazard ratio was 0.464 (0.442–0.487) in the unmatched cohort and was 0.492 (0.457–0.530) in the matched cohort. A dose-response pattern was observed while comparing the tertiles of cumulative duration, cumulative dose and defined daily dose of metformin therapy to never users in all analyses. A risk reduction of approximately 40–50% was consistently observed in various sensitivity analyses. Conclusion: Chronic therapy with metformin in patients with type 2 diabetes mellitus is associated with a lower risk of hemorrhoid. ? Copyright ? 2021 Tseng. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101992455&doi=10.3389%2ffphar.2020.578831&partnerID=40&md5=ec5a60ed47fcec394dc5ef58840a4c09 https://scholars.lib.ntu.edu.tw/handle/123456789/558306 |
ISSN: | 1663-9812 | DOI: | 10.3389/fphar.2020.578831 | SDG/關鍵字: | metformin; adult; aged; Article; cohort analysis; controlled study; disease association; dose response; female; hemorrhoid; hemorrhoidal venous plexus; human; long term care; low risk patient; major clinical study; male; national health insurance; non insulin dependent diabetes mellitus; outcome assessment; propensity score; retrospective study; risk assessment; risk reduction; Taiwan; treatment duration |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。